Participation in any clinical investigation or use of other investigational drugs at time of enrollment

A history of clinically significant ECG abnormalities

History of malignancy of any organ system

Smokers (use of tobacco products in the previous 3 months)

Use of prescription drugs other than those required for control and relief of asthma

Use of oral steroids within 12 weeks prior to dosing

FEVI \< 80% predicted at screening or baseline

Use of albuterol more than twice a week for relief of asthma

Patients suffering from active hay fever at baseline or likely to require treatment during the study

History of chronic respiratory disease other than asthma or chronic allergic rhinitis

Emergency room visit within 6 weeks of screening due to asthma

Hospitalization for asthma in the last year

History of intubation/assisted ventilation for asthma in the last 5 years

Administration of live vaccines within the preceding month

To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma